Efficacy and Safety of Fixed-Dose Combination of Empagliflozin-Sitagliptin-Metformin ER versus Dapagliflozin-Sitagliptin-Metformin ER in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Phase III Randomized Double-Blind Trial
Journal of Diabetology · 2026-07 · 17 (4) · 371-378
DOI: 10.4103/jod.jod_21_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetology, online erschienen am 28.07.2026. Verfasst von Prashant Kumthekar und 4 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To evaluate the efficacy, safety, and tolerability of two fixed-dose combinations (FDCs) of empagliflozin, sitagliptin, and metformin extended release (ER) with dapagliflozin, sitagliptin, and metformin ER FDC in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin monotherapy. Materials and Methods: This was a multicenter ( n = 16), randomized, double-blind, active-controlled, phase III study (Clinical Trials Registry - India/2024/04/066077) conducted across India, between May 2024 and January 2025. The patients were randomized (1:1:1) to receive FDC of empagliflozin 10 mg/sitagliptin 100 mg/metformin 1000 mg ER (Arm A); empagliflozin 25 mg/sitagliptin 100 mg/metformin 1000 mg ER (Arm B); dapagliflozin 10 mg/sitagliptin 100 mg/metformin 1000 mg ER (Arm C). The primary endpoint was the mean change in glycated hemoglobin (HbA1c) at week 16. Secondary endpoints included changes in fasting plasma glucose (FPG) and postprandial glucose (PPG). Adverse events (AEs) were recorded as part of the safety assessment.
Results
A total of 315 patients were included in the study: Arm A ( n = 104), Arm B ( n = 106), and Arm C ( n = 105). At week 16, Arm B (−1.77%) demonstrated a significant reduction in HbA1c compared to Arm A (−1.54%) and Arm C (−1.53%). Arm B (−49.51 mg/dL) also showed a significant reduction in FPG compared to Arms A and C. Changes in PPG, body weight, systolic blood pressure, and glycemic target attainment were comparable across arms. All treatments were well tolerated, with no serious AE or significant laboratory abnormalities.
Conclusion
Both empagliflozin FDCs showed improvement in glycemic parameters and were well tolerated. Arm B demonstrated a significant reduction in HbA1c and FPG compared to other arms. Trial Registration: CTRI/2024/04/066077
Zitieren
APA
Kumthekar, P., Upadhyay, M., Mirajkar, S., Barge, V. B., & Bhattacharya, R. (2026). Efficacy and Safety of Fixed-Dose Combination of Empagliflozin-Sitagliptin-Metformin ER versus Dapagliflozin-Sitagliptin-Metformin ER in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Phase III Randomized Double-Blind Trial. Journal of Diabetology, 17(4), 371-378. https://doi.org/10.4103/jod.jod_21_26
Vancouver
Kumthekar P, Upadhyay M, Mirajkar S, Barge VB, Bhattacharya R. Efficacy and Safety of Fixed-Dose Combination of Empagliflozin-Sitagliptin-Metformin ER versus Dapagliflozin-Sitagliptin-Metformin ER in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Phase III Randomized Double-Blind Trial. Journal of Diabetology. 2026;17(4):371-378. doi:10.4103/jod.jod_21_26
BibTeX
@article{Kumthekar2026,
author = {Kumthekar, Prashant and Upadhyay, Mihir and Mirajkar, Sunil and Barge, Vijaykumar Bhagwan and Bhattacharya, Raja},
title = {Efficacy and Safety of Fixed-Dose Combination of Empagliflozin-Sitagliptin-Metformin ER versus Dapagliflozin-Sitagliptin-Metformin ER in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Phase III Randomized Double-Blind Trial},
journal = {Journal of Diabetology},
year = {2026},
volume = {17},
number = {4},
pages = {371--378},
doi = {10.4103/jod.jod_21_26}
}
EUVIMED